Aktis Oncology raised $175M in a Series B
Aktis Oncology
- Location: Boston, MA
- Amount Raised: $175M
- Funding Stage: Series B
- Description: Aktis Oncology is focused on developing targeted radiopharmaceuticals for treating solid tumors.
- Key Investors: RA Capital Management, RTW Investments, Janus Henderson Investors, T. Rowe Price, Avidity Partners, Bristol Myers Squibb, Eli Lilly, MRL Ventures Fund
Aktis Oncology offers a unique opportunity for professionals passionate about transforming cancer treatment. The company is at the forefront of developing targeted radiopharmaceuticals aimed at treating solid tumors, which positions it as a leader in cutting-edge oncology innovation. With a recent $175M Series B funding and backing from prominent investors such as RA Capital Management, Bristol Myers Squibb, and Eli Lilly, Aktis Oncology is poised for significant growth. Working here means being part of a mission-driven team committed to advancing cancer therapies, while also benefiting from the stability and support of top-tier investors.